DPP4 Activity Assay Kit
- Known as:
- DPP4 Activity Assay Kit
- Catalog number:
- K779-100
- Product Quantity:
- 100 assays
- Category:
- Peptides
- Supplier:
- Biovis
- Gene target:
- DPP4 Activity Assay Kit
Related genes to: DPP4 Activity Assay Kit
- Gene:
- DPP4 NIH gene
- Name:
- dipeptidyl peptidase 4
- Previous symbol:
- CD26, ADCP2
- Synonyms:
- DPPIV
- Chromosome:
- 2q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-05
- Date modifiied:
- 2016-02-05
Related products to: DPP4 Activity Assay Kit
Human ELC ELISA KIT 96 TEST
OxiSelect Hydroxyl Radical Antioxidant Capacity (HORAC) Activity Assay, Trial Size
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size guanine nucleotide binding protein alpha inhibiting activity polypeptide 1 (GNAI1) polyclonal antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit Related articles to: DPP4 Activity Assay Kit
- India faces a growing burden of type 2 diabetes mellitus (T2DM), necessitating innovative treatments that improve glycemic control, reduce glycemic variability (GV), and enhance patient adherence. Dipeptidyl peptidase 4 (DPP-4) inhibitors are established antidiabetic agents; however, once- or twice-daily dosing often limits long-term compliance. Trelagliptin, a novel once-weekly DPP-4 inhibitor, addresses this issue with an extended half-life and superior molecular stability, enabling sustained DPP-4 inhibition and significant GV reduction. Improved glycemic control with trelagliptin can potentially lower the risk of macrovascular and microvascular complications associated with T2DM. Trelagliptin, developed and launched in India by Zuventus Healthcare Limited under the brand name Trelaglip®, offers prolonged efficacy and high selectivity in inhibiting the DPP-4 enzyme, helping minimize side effects. Development began with in-house active pharmaceutical ingredient (API) synthesis, followed by successful formulation and stability studies. A bioequivalence study confirmed pharmacokinetic equivalence with the reference product by Takeda, Japan. In a randomized phase 3 clinical trial involving patients with glycated hemoglobin (HbA1c) ≥8%, trelagliptin showed greater HbA1c reduction (-1.25%) as compared to vildagliptin (-1.15%) and a similar safety profile. Mild adverse events occurred in 6.67% of trelagliptin users compared to 9.17% with vildagliptin. This article outlines the development and regulatory journey leading to trelagliptin's first approval in India by the Central Drugs Standard Control Organization (CDSCO) in December 2024. Phase 4 real-world evidence studies are currently ongoing in India to assess long-term safety and efficacy. - Source: PubMed
Dewan BhupeshNavale SanjaykumarShinde SiddheshwarGaniga Rishima - Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for type 2 diabetes (T2D) and obesity, may modulate reward pathways and reduce substance-related behaviors. This study assessed the association between GLP-1RA use and substance use-related hospitalization in older adults with coexisting T2D and substance use disorders (SUD). - Source: PubMed
Publication date: 2025/09/15
Dai HaoRadwan Rotana MScheiffele Grant DTang HuilinSheer AmyLin Hsin-YuehZhang PengyueAdirika DarleneLuong KateBian JiangGuo Jingchuan - DPP4 is a crucial target for diabetes, and whether ginsenosides derived from can exert their hypoglycaemic effects by inhibiting DPP4 has not been reported yet. To solve this issue, our study used affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method to screen DPP4 inhibitors from , and finally total 7 ginsenosides belonging to oleanane-type saponins were screened out. Our study systematically screened and identified DPP4 inhibitors from for the first time, and the results revealed that inhibiting DPP4 activity so as to produce hypoglycaemic effects probably was another important mechanism for ginsenosides exerting hypoglycaemic effects, which was attributed to oleanane-type saponins but not protopanaxadiol-type and protopanaxatriol-type saponins. - Source: PubMed
Publication date: 2025/09/15
Wang Hong-PingZhao ChenWang Zi-JianLin Zhao-ZhouZhang Zhao-Hua - This case report describes a 61-year-old male with Charcot-Marie-Tooth disease type 1A (CMT1A) who developed poorly controlled type 2 diabetes mellitus. The patient, with a history of CMT1A, was admitted for preoperative glycemic management prior to lumbar spinal stenosis surgery, exhibiting an HbA1c of 8.1%. Treatment with metformin had been insufficient. Considering potential insulin resistance due to decreased skeletal muscle mass from CMT and reduced mobility, a combination therapy of the DPP-4 inhibitor sitagliptin and the SGLT2 inhibitor empagliflozin was initiated post-surgery, alongside diet and exercise. Notably, this combination effectively improved glycemic control without reducing skeletal muscle mass. This suggests that the combination of a DPP-4 inhibitor and an SGLT2 inhibitor may be a viable therapeutic option for managing diabetes mellitus in patients with CMT, warranting further investigation in larger studies due to the rarity of this comorbidity. Long-term glycemic control is crucial for maintaining activities of daily living (ADLs) and quality of life (QOL) in these patients. - Source: PubMed
Publication date: 2025/08/12
Wada MakotoMizuno YuriKajiyama AmikaToriumi ShujiHashimoto TakahideOhtake NaokiYamaga MasayaYoshida TomohikoMurai HiroyukiTakemoto Minoru - This randomized controlled trial (RCT) was designed to evaluate the effects of sitagliptin on diabetic foot ulcers (DFUs). - Source: PubMed
Gao WeiChen DaweiHe HuaJiang NenggangChen LihongRan Xingwu